Myriad Genetics (MYGN) Down on Q4 Numbers

Myriad Genetics, Inc. MYGN shares fell 34.2% to $19.40, after the company posted weaker-than-expected Q4 results and issued a downbeat guidance. Share volume was 11.4 million, compared to an all-day average of less than one million